Skip to search formSkip to main contentSkip to account menu

palbociclib

Known as: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one 
An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent… 
National Institutes of Health

Related topics

Related topics

16 relations

Broader (4)

Antineoplastic AgentsPiperazinesProtein Kinase InhibitorsPyridines
Cyclin-Dependent KinasesGene Expression RegulationKinase Inhibitors [MoA]NCIt Antineoplastic Agent Terminology

Narrower (1)

PD 0332991

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).
1057 Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are widely used for pts with HR+/HER2- MBC. The MONARCH-1 trial… 
2018
2018
Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial
BACKGROUND: The CDK4/6 inhibitor palbociclib in combination with fulvestrant (F) improved progression-free survival (PFS) vs F… 
Review
2017
Review
2017
Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
ABSTRACT Background: Cyclin-dependent kinase (CDK) inhibitors emerge as efficacious agents in hormone positive metastatic breast… 
Highly Cited
2017
Highly Cited
2017
Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy
Here, we performed high-throughput drug-screening to identify new non-toxic mitochondrial inhibitors. This screening platform was… 
2016
2016
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Palbociclib is a cyclin-dependent kinase (CDK) 4/CDK6 inhibitor approved for breast cancer that is estrogen receptor (ER… 
2016
2016
Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).
512Background: PALOMA-3 is a randomized, double-blind, phase III study comparing P+F with fulvestrant plus placebo (F+Pla) in pre… 
2016
2016
New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies
Although major advances in our understanding of the molecular underpinnings of hormone receptor–positive (HR+) breast cancer have… 
2015
2015
Another Beginning for Cystic Fibrosis Therapy.
Treatments for the fundamental defect in cystic fibrosis are beginning to come to fruition. Cystic fibrosis, an autosomal… 
2015
2015
Does CDKN2A loss predict palbociclib benefit?
Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and… 
Highly Cited
2014
Highly Cited
2014
Molecular Pathways Molecular Pathways : CDK 4 Inhibitors for Cancer Therapy
Unrestrained growth is the hallmark of cancer, and disrupted cell-cycle regulation is, therefore, common. CDK4 is the key… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)